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Abstract Telomerase has been recognized as a relevant
factor distinguishing cancer cells from normal cells. Thus,
it has become a very promising target for anticancer ther-
apy. The cell proliferative potential can be limited by
replication end problem, due to telomeres shortening,
which is overcome in cancer cells by telomerase activity or
by alternative telomeres lengthening (ALT) mechanism.
However, this multisubunit enzymatic complex can be
regulated at various levels, including expression control but
also other factors contributing to the enzyme phosphory-
lation status, assembling or complex subunits transport.
Thus, we show that the telomerase expression targeting
cannot be the only possibility to shorten telomeres and
induce cell apoptosis. It is important especially since the
transcription expression is not always correlated with the
enzyme activity which might result in transcription mod-
ulation failure or a possibility for the gene therapy to be
overcome. This review summarizes the current state of
knowledge of numerous telomerase regulation mechanisms
that take place after telomerase subunits coding genes
transcription. Thus we show the possible mechanisms
of telomerase activity regulation which might become
attractive anticancer therapy targets.
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Introduction
Telomeres, the guanine-rich repeated sequences located at
the ends of chromosomes, function as a biological clock
limiting the cell proliferation ability with every next cell
division (Hayﬂick limit). However, most cancer cells
reveal a telomere length maintenance mechanism (TMM)
which is responsible for telomeres rebuilt that accompanies
cellular proliferation [1]. Majority of cancer cells demon-
strate the chromosome ends renewal mechanism involving
telomerase, that utilizes its integral RNA molecule as a
template for reverse transcription of new telomeric DNA.
Other cell lines use a non-telomerase mechanism, known as
Alternative Lengthening of Telomeres (ALT) which
involves the use of a DNA template [2]. The telomere
lengthening is either undetectable or has low level of
activity in normal somatic cells while it is rather common
in the vast majority of cancers [3, 4]. Thus it provides
important target for detection and treatment of cancer cells.
Generally, the length of telomeres varies between 2 and
15 kb in germline cells [5, 6], whereas in human ALT cell
lines, telomere length varies between 2 and over 50 kb
[7, 8]. The studies across many tumor types [9] have shown
that the majority (*85%) of tumors express telomerase
and hence are able to maintain a stable and homogenous
telomere length and so avoid replicative senescence. The
remaining *15% of tumors either do not maintain telo-
mere length or they activate ALT [7]. For example almost
100% of adenocarcinomas express telomerase [10] whereas
the ALT mechanism among the sarcomas is much more
common i.e. *47% in osteosarcomas and *34% in
astrocytomas [11], *25% in liposarcomas [12, 13]. The
reasons for the tissue difference in the utilization of telo-
merase or ALT is not understood but it has been proposed
that telomerase (TERT expression) may be more heavily
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known that ALT positive primary tumors can give rise to
telomerase-positive secondary tumors and vice versa [14].
Furthermore, there is evidence that both TMMs can be
active in the same cell line and similarly that a small
proportion of tumors express telomerase and markers for
the ALT mechanism [12, 13]. There is the interest in
targeting novel anticancer therapies at telomerase but
tumors that utilize the ALT mechanism will not respond
to such therapies. Thus quadruplex stabilizers appear to
be the most promising strategies against ALT revealing
cancers.
It was demonstrated in many studies that telomeres
renewal is a multifactorial process in mammalian cells,
involving telomerase gene expression, post-translational
protein–protein interactions and protein phosphorylation
(see Table 1). Numerous proto-oncogenes and tumor sup-
pressor genes are also engaged in this mechanism and the
complexity of telomerase control mechanisms is studied in
the context of tumor development as well as ageing. Due to
signiﬁcant role of telomerase in those processes it is of
great interest to identify the enzyme regulators. Addition-
ally, since numerous studies reveal a correlation between
short telomere length and increased mortality, the telome-
rase expression/activity appears to be one of the most
crucial factors to study in order to improve the anticancer
therapy and prevention. Thus, the enzyme seems to be the
most promising target for therapy. However, because both,
telomerase expression and activity, are not always corre-
lated, targeting complex activity seems to be of great
interest.
Telomerase splicing variants
Alternative mRNA splicing is a common mechanism that
controls gene expression in higher eukaryotes and this
process is known to be tissue-, development- and
sex-speciﬁc [16]. The same phenomenon concerns TERT
expression that can be alternatively spliced and different
variants of that gene can be observed e.g. in testis and
colonic crypt, suggesting complex regulation of this gene
in the development [17–19].
TERT
As already reported, TERT splice variants may be
expressed in normal, pre-crisis, and alternative lengthening
of telomeres cells (ALT) that lack detectable telomerase
activity [17–19]. Thus, transcriptional control of TERT is
supposed to play the crucial role in the complex regulation
of telomerase activity, however alternative splicing
variants are also suggested to play an important role in
telomerase regulation. Ten different splice variants of
TERT have been identiﬁed so far [17, 18, 20, 21]. The most
relevant and widely studied variants involve splicing at two
main sites: the a splice site and the b site [18, 19]. The a
site deletion of 36 bp from exon 6 within reverse trans-
criptase (RT) motif A does not inﬂuence translation pro-
cess [17, 22]. The other deletions from exons 7 and 8
(b site, 182 bp) and one insertion (38 bp) cause premature
Table 1 Human telomerase regulation factors
Factor Up(:)/down(;)
regulation
References
Phosphorylation
Akt : [60]
Estrogen
a : [120]
Insulin-like growth factor I (IGFI)
a : [65, 122]
Interleukin 6 (IL-6)
a : [66]
Interleukin 2 (IL-2)
a : [125]
PKC (izoforms a,ß ,d, e, f) : [66, 68, 70]
Ionizing radiation
a : [125]
Ultraviolet irradiation
a : [126]
dimethyl sulfoxide (DMSO)
a : [126]
Abl ; [55]
PP2A ; [57]
Imatinib mesylate (Gleevec)
a ; [117]
PTEN
a ; [118]
Gambogic acid
a ; [62]
Retinoic acid
a ; [119]
Mistletoe lectin
a ; [121]
IP6 (inositol hexaphosphate)
a ; [67]
Oxygen
a ; [124]
Transport
14-3-3 signaling proteins : [74]
NF-jBp65 : [75]
Shp-2 : [76]
Nucleolin : [81]
H2O2
a ; [77]
Ran (GTPase)
a ; [77]
hPinX1 ; [80]
Complex assembly
hnRNPA1 : [98]
TCAB1 : [99]
POT1 : [104]
TPP1 : [104]
TRF1, TRF2 ; [109]
Ku ; [117]
hRap1
a ; [113]
Arrows indicate activation (:) or inhibition (;) of telomerase activity
a Indirect inﬂuence on telomerase activity
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123translation terminations upstream of the essential RT
motifs effectively deleting the remaining three reverse
transcriptase motifs [23, 24]. Splicing at either site can
occur independently or in combination to produce differ-
ent full-length variants at different proportions within
various cancer cell lines [25]. To date, only the a-/b?
variant has been shown to exhibit any regulatory function,
acting as a dominant-negative inhibitor of telomerase
activity when overexpressed in either normal or tumor
cells [25, 26]. These variants do not have catalytic
activity since the RT motifs are required for this function
[23, 24].
Another deletion variant of the TERT transcript was
identiﬁed in hepatocellular carcinoma cell lines [20]. The
deleted transcript was characterized by an in-frame dele-
tion of 189 bp, spanning nucleotides 2710 to 2898, corre-
sponding to the complete loss of exon 11 (gamma-
deletion). Interestingly, in gastric and hepatocellular car-
cinoma cell lines, the gamma deletion variant and its
combination variants, a- and c-, b- and c-, a-, b- and
c-deletion variants were frequently detected, while they
were not detected in colorectal carcinoma cell lines [27].
The other three insertions occur downstream of the RT
motifs and produce truncations of the protein. Since some
C-terminal modiﬁcations have been shown to interfere with
the ability of telomerase to maintain telomeres [28, 29],
these insertion variants may not produce biologically
functional proteins [25]. In the studies performed in oste-
osarcoma [30] it was concluded that in cell lines exhibiting
full-length TERT mRNA/protein without any splice vari-
ants telomerase activity was higher than in cell lines
expressing splice variants. It was also demonstrated that
alternative splicing might be involved in controlling the
telomerase activity in osteosarcoma cell lines, thereby
contributing to the telomere maintenance mechanism.
However, it is still unclear whether the ratio of full length
to spliced TERT is important in determining telomerase
activity [31]. In some studies it was shown that the absolute
expression of TERT was well correlated with telomerase
activity [32–35], while in other no correlation with either
relative or absolute amounts of variant transcripts was
revealed [36]. Thus, the regulatory function of various
TERT transcripts is supposed to be cell type–speciﬁc,
however, the many different methods used to quantify
TERT mRNA in multiple studies [30, 36–46] made it
difﬁcult to standardize these ﬁndings [47]. It was also
shown that the alternative splicing could be regulated by
changes in the subcellular re-localization of splicing factors
[48]. Accordingly, it was suggested that TERT could be
regulated by TGF-b1 through alternative splicing [38].
Alternatively, TGF-b1 might induce rapid degradation of
the TERT transcripts whereas c-Myc preferentially stabi-
lizes the b variant.
Splicing variants of POT1
It was shown that human POT1 protein (protection of
telomeres, hPOT1) known to bind speciﬁcally to the G-rich
telomere strand could act as a telomerase-dependent,
positive regulator of telomere length [49]. In addition to
full-length POT1 protein (variant v1), the human POT1
gene encodes four other variants due to alternative RNA
splicing (variants v2, v3, v4, and v5), whose functions are
poorly understood [50]. Importantly, a COOH-terminally
truncated variant (v5), which consists of the NH2-terminal
oligonucleotide-binding (OB) folds and the central region
of unknown function, was found to protect telomeres and
prevent cellular senescence as efﬁciently as v1. However,
detailed mechanistic and functional differences between v1
and v5 were found [50] but their contribution to whole
enzyme activity remains to be elucidated.
Posttranslational regulation
Transcriptional regulation is a crucial stage affecting tel-
omerase activity, however, it has been well documented,
that the regulation of the holoenzyme takes place during
posttranslational mechanism and plays a pivotal role in
modulating telomerase activity as well [51]. Posttransla-
tional regulation of telomerase activity can occur via
reversible phosphorylation of TERT catalytic subunit at
speciﬁc serine/threonine or tyrosine residues [51]. Due to
multiple kinase and phosphatase activators and inhibitors
the telomerase phosphorylation status may affect its
structure, localization and enzyme activity [51]. Numerous
non-speciﬁc phosphorylation sites within TERT protein are
postulated but only a few of them appear to be the key
residues, and their phosphorylation inﬂuences telomerase
activity (both, activation and inhibition) [52].
Telomerase repression
c-Abl
Speciﬁc phosphorylation site at TERT is present at proline-
rich region (308-PSTSRPPRP-316) [51]. It was revealed
that the contribution of c-Abl tyrosine kinase to TERT
phosphorylation at speciﬁc tyrosine residue led to
decreased telomerase activity. It was shown that overex-
pression of c-Abl inhibited cell growth by causing cell
cycle arrest [53]. Because of c-Abl’s role in stress response
to DNA damage, exposure of cells to ionizing radiation led
to a signiﬁcant increase in TERT phosphorylation by c-Abl
[54]. It was also demonstrated that c-Abl phosphorylated
TERT leading to inhibition of telomerase activity and
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ciation between c-Abl and TERT. A crosstalk between Bcr-
Abl tyrosine kinase, protein kinase C and telomerase was
also suggested as a potential reason for resistance to Glivec
in chronic myelogenous leukemia [55].
PP2A
Protein phosphatase 2A (PP2A), which is engaged in the
negative control of cell growth and division, reveals
inhibitory function on telomerase activity in human breast
cancer, PMC42 cells. As reported, PP2A remarkably
abolished telomerase activity in nucleus while this effect
was not observed when the other main cellular protein
phospatases 1 and 2B were applied [56]. When active,
PP2A dephosporylates TERT protein on Ser and/or Thr
residue [57]. Another study showed that PP2A caused
dephosphorylation of Akt kinase on Ser and/or Thr residue
and thus abolished its activatory effect on TERT. However,
it is still unclear if PP2A might directly dephosphorylate
TERT without protein–protein interaction [58]. The effect
of PP2A on TERT is blocked by its inhibitor, okadaic acid.
Thus, endogenous protein kinase(s) might again phos-
phorylate telomerase catalytic subunit and reactivate the
protein. It was then concluded that TERT phosphorylation
and dephosphorylation was crucial to telomerase activity
regulation in human breast cancer cells [56]. Another
studies revealed that PP2A was a direct target for simian
virus 40, since this phosphatase is inhibited by viral
oncogenic protein small-t antigen binding and conse-
quently, the cell proliferation is stimulated. These data
suggested the mechanism of telomerase activation and
tumor genesis by oncogenic viruses [59]. Thus, pharma-
cological stimulation of PP2A dephosphorylation of telo-
merase in cancer may be of potential therapeutic
signiﬁcance.
Telomerase activation
PKB
The Akt kinase (known also as protein kinase B) shows a
speciﬁcity to serine/threonine residues and enhances
human telomerase activity through TERT phosphorylation.
This explains Akt kinase’s role in protecting cell from
apoptosis and augmenting the cell proliferation capacity. It
was shown in melanoma cells, that Akt kinase carried out
this modiﬁcation on serine residue at position 824 of TERT
protein [60]. Phosphorylation at two different sites is nec-
essary to activate Akt kinase (Ser473 and Thr308) [61].
However, some studies showed that Akt phosphorylation at
serine 473 residue inﬂuenced subsequent phosphorylation
of the TERT subunit. The authors also showed that Akt
submitted to dephosphorylation at Ser473 by gambogic
acid (GA, a natural antitumor compound) caused a
decrease in TERT phosphorylation through Akt and sub-
sequently decreased telomerase activity. Thus, Akt was
suggested to be a limiting factor for human telomerase
activity, especially since it plays a crucial role in human
telomerase activity regulation through TERT phosphory-
lation at PI3K/Akt/mTOR pathway-dependent posttran-
scriptional level [62].
In physiological conditions down-regulation of telome-
rase activity takes place during differentiation of CD8? T
cells since it is crucial to maintain the replicative capacity
of memory T cells. However, CD8? T cells may lose their
ability to phosphorylate Akt kinase during gradual differ-
entiation. Telomerase down-regulation in highly differen-
tiated CD8?CD28-CD27- T cells leads to inevitable
replicative end stage after their activation [63]. It was
shown that TERT was associated with both, Akt and the
heat shock protein HSP90 in human embryonic kidney and
endothelial cells. This association is necessary for telo-
merase activity by Ser473 phosphorylation of its catalytic
subunit while HSP90 prevents Akt kinase dephosphoryla-
tion (inactivation) by protein phosphatase 2A (PP2A) and
consequently decrease of telomerase activity [59]. Another
study demonstrated that novobiocin (competitive inhibitor
of HSP90) [64] inhibited formation of the Akt and Hsp90
complex and resulted in dephosphorylation and inactiva-
tion of Akt [58]. Additionally, it was shown that the pro-
liferative and survival factors for human multiple myeloma
(MM) cells, i.e. interleukin 6 (IL-6) and insulin-like growth
factor 1 (IGF-1) up-regulated telomerase activity without
alteration of human telomerase reverse transcriptase
(TERT) protein expression [65]. As reported, that increase
of telomerase activity caused by these cytokines was
mediated by phosphatidylinositol 30-kinase (PI3k)/Akt/
nuclear factor jB (NFjB) signaling. Thus telomerase
activity was shown to be related not only to transcriptional
regulation of TERT by NFjB but also to posttranscrip-
tional regulation because of phosphorylation of TERT by
Akt kinase. These studies therefore demonstrated that tel-
omerase activity was associated with cell growth, survival,
and drug resistance in MM cells.
PKC
First studies of PKC (protein kinase C) in breast cancer
cells showed that PKCa phosphorylated both, TERT and
human telomerase associated protein 1 (hTEP1) [66]. It
was shown that inositol hexaphosphate (IP6) repressed
telomerase activity via deactivation of Akt and PKCa
(Ser657) in prostate cancer cells [67]. Consequently, the
lack of TERT phosphorylation makes impossible to bind its
3342 Mol Biol Rep (2011) 38:3339–3349
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forced to go back from nucleus to cytoplasm. Thus, it was
proposed that IP6 may also decrease the level of proteins
involved in telomerase transport to the nucleus [67]. Other
studies performed in human nasopharyngeal carcinoma
(NPC) cells showed that telomerase activity is controlled
by PKCf isoform that phosphorylates TERT [68]. This
kinase was postulated to be critical for phosphorylation of
TERT (thus telomerase activation) during T cell activation
as well. However, the participation of other PKC isoforms
has not been excluded. The same author reported that in T
lymphocytes the PKC activity was essential not only for
post-transcriptional control of telomerase activity but also
for induction of its expression through PKC-dependent
signal pathway and induction of c-Myc expression [69].
The research on head and neck cancer cells revealed that
expression of PKC isoenzymes a, b, d, e and f and TERT
phosphorylation was also correlated with higher telomerase
activity in tumor cells [70].
Transport
When posttranslational modiﬁcation are brought to an end,
two main subunits of telomerase (TERT and TR) are
delivered to the place of their action, nucleus.
TERT nuclear transport
InnonactivatedCD4?Tcellstelomeraseactivityisdetected
only in cytoplasm. However, in activated T cells, the TERT
proteinispresentinboth,cytoplasmandnucleus.Thus,total
cellularamountofTERTremainsconstant—beforeandafter
activation, while transport of TERT from cytoplasm into
nucleus takes place during T cells activation. Consequently,
higher telomerase activity is observed in activated T cells
which leads to telomere elongation in nucleus [71]. It is not
clear yet whether TERT is transported into nucleus ﬁrst,
followed by telomerase complex assembly or if the whole
telomerase complex is transferred into nucleus. Based on
certain research, a hypothesis that TERT is transported into
nucleuswheretelomerasecomplexisassembledseemstobe
more likely. It is supported by the fact that the vast majority
of TR (human telomerase RNA) [72] as well as p23 and
Hsp90 (telomerase complex components) are present in
nucleus[73].SeveralfactorsinvolvedinTERTtranslocation
intothenucleushasbeenidentiﬁed.Itwasdemonstratedthat
TERT binds to the 14-3-3 signaling proteins. This associa-
tioniscrucialforlocalizationofTERTinthenucleuswhileit
doesnotaffecttelomeraseactivity.The14-3-3proteinsactas
repressorsofTERTafterbindingtoareceptorforthenuclear
export machinery (CRM1/exportin1) [74]. Another studies
showed that TERT protein interacts directly with nuclear
factorNFjBp65inmultiplemyelomacellswhichsuggested
that this factor modulated nuclear translocation of telome-
rase and played a crucial role in its regulation. Tumor
necrosis factor a (TNF a) activates NFjB p65 that causes an
increase in translocation of TERT bound to NFjB p65 from
the cytoplasm to the nucleus. Moreover, this factor binds
only phosphorylated TERT [75], thus other researchers
concluded that Shp-2 (SH2-containing protein tyrosine
phosphatase) might participate in the nuclear transport of
TERT as well and suggested that Shp-2 is a negative regu-
lator of Src mediated export. They also showed that in
nucleus the Shp-2 was associated with TERT, but the com-
plex dissociated just before TERT export. It was revealed
that Shp-2 activity was signiﬁcant for retaining TERT in the
nucleus [76]. Itwas also shown that H2O2 treatment induced
translocation of TERT from the nucleus into the cytoplasm.
ROS-induced phosphorylation of tyrosine 707 within TERT
is crucial for this nuclear export and Src kinase family is
responsible forthis modiﬁcation. Nuclear export of TERT is
a speciﬁc mechanism because it is connected with mitogen-
activated protein kinase1/2 (MAPK1/2) import to the
nucleus. When theTERT moleculeisphosphorylatedbySrc
kinase it binds with Ran (GTPase) that enables nuclear
export of TERT via CRM1-related mechanism [77]. After
TERT translocation from cytoplasm to nucleus the sub-
sequent shuttling to the nucleolus (in normal cells) takes
place [78]. However, in cancer cells, TERT protein is dis-
tributed mainly in nucleoplasm, where substrates for telo-
merase are present [79]. As reported, one of the nucleolar
protein hPinX1 bound to TERT and therefore inhibited tel-
omerase enzymatic activity [80]. Recent studies revealed
that hPinX1 also increased the TERT transport from nucle-
oplasmtonucleolus.Itwasproposedthatthesetwofunctions
of hPinx1 protein are independent from each other [79]. The
other authors suggested that telomerase retaining in the
nucleolus might prevent from interaction with its substrates
present in nucleoplasm [78]. Despite binding of TERT with
hPinX1, it can associate with TR and form a telomerase
holoenzyme. This complex is stored in nucleolus where
its function is kept dormant till cell division signal [78].
Nucleolin, a nucleolus protein, forms a complex with telo-
meraseandfacilitatestheexportoftelomerasefromnucleoli
to the nucleoplasm. This process may involve masking of a
nucleolar retention signal of TERT and/or nucleolin. It is
supposed that nucleolin maintains telomerase in the nucle-
oplasm and therefore makes it ready for the delivery to the
telomeres [81].
TR nuclear transport
As shown, translocation of TR and TERT is regulated and
multiple nuclear structures participate in transport and
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cycle TR is present in Cajal bodies that act as its trans-
mitters to telomeres [83]. These subnuclear structures are
general sites of RNP assembly and RNA modiﬁcation [84].
In contrary to TR, TERT is located in distinct nucleo-
plasmic foci and thus, two main subunits of telomerase are
separated during almost the whole cell cycle. In early S
phase TERT is translocated to nucleoli. At the same time
Cajal bodies containing TR accumulate at the periphery of
nucleoli. Interestingly, TR accumulates at the pole of Cajal
body that precedes localization to telomeres in mid-S phase
when Cajal bodies deliver telomerase to individual telo-
meres. Furthermore, it was revealed that the same kinases
and phosphatases that act during S-phase may modify tel-
omerase subunits [82]. However, the mechanisms involved
in targeting and accumulation of TR is not fully under-
stood. To date, within telomerase RNA molecule the CAB
box and H/ACA motif has been identiﬁed to inﬂuence the
TR translocation to Cajal bodies and nucleoli [85, 86].
Analogically, one of TERT domain is known to mediate
nucleolar translocation [87, 88].
Telomerase complex assembly
Human telomerase assembly occurs by complex mecha-
nism consisted of few steps, depending on energy and
involving ﬁrst of all stabilization of TR and its subsequent
association with TERT protein [52, 89]. Only TERT pro-
tein and TR are necessary to gain telomerase activity in
vitro. However, in vivo telomerase complex is composed
of additional multiple proteins (see Fig. 1), that facilitate
the enzyme to act [90]. Similarly to the transport of telo-
merase subunit TERT to the nucleus, assembly of the tel-
omerase enzyme complex may be regulated during cell
cycle. Telomerase assembly could take place during S
phase and it is disassembled probably during M phase.
Prevention of premature binding of the essential telomerase
subunits (TERT and TR) is possible due to different sites of
their compartmentalization and keeping them away from
their substrates (telomeres) [82]. Thus, two telomerase
assembling sites are possible during S phase i.e. at the
telomere ends (similarly to yeast) [91] or in Cajal bodies
[82]. It has been suggested that survival of motor neuron
(SMN) complex, a RNP assembly factor present in Cajal
bodies, takes part in telomerase biogenesis. It was dem-
onstrated that TR is associated with GAR1, a protein which
interacts with SMN complex [92]. However, it requires
further analysis to establish where does the telomerase
assembly occur. Recent studies showed that the localiza-
tion of TR in Cajal bodies and near telomeres depends on
TERT. This suggests that TR assembles a complex with
TERT and then both proteins are transported to telomeres.
Alternatively, TERT is supposed to indirectly inﬂuence the
trafﬁcking of TR or a transient interaction of the two
components that contribute to TR localization [93].
Telomerase RNA goes pseudourdylation by w synthase
dyskerin. This RNA modiﬁcation is essential for assembly
and stability of TR. Then, three additional H/ACA proteins
bind: Nop10, Nhp2 and Gar1. Nop10 associates with Cbf5
(dyskerin homolog in yeast) which makes a core in TR
complex. Association of other subunits (La, Staufen, L22
and hnRNP C1/C2, TEP1, p23 and Hsp90) enables stabil-
ization and ﬁnal structure formation [52, 73, 94]. However,
the roles of these proteins in telomerase action is still
unclear and further investigation is required.
ATPases and DNA helicases pontin and reptin reveal an
essential role in telomerase assembly. The amount of
TERT bound to pontin and reptin peaks in S phase [95].
When the two pivotal subunits of telomerase enzyme are
stabilized and bound with auxiliary proteins the TERT and
TR dimerization occurs. Two regions of TR are necessary
for its binding with TERT: the template region (nucleotides
44-186) and a putative double hairpin element in the 50 stem
of the H/ACA domain, where TR stabilizing H/ACA pro-
teins bind (nucleotides 243-326) [96].
Single-molecule ﬂuorescence two-color coincidence
detection technique (TCCD) made possible to show that
active human telomerase comprises of TERT and TR in a
1:1 stoichiometry ratio [97]. When telomerase assemblage
is ﬁnished, hnRNP A1 association with TR is required for
holoenzyme access to telomeres. hnRNP A1 can bind
simultaneously with TR and telomeric DNA and therefore
acts as a potential link between telomerase enzyme and
telomeres [98]. Recently, a novel protein TCAB1 (telo-
merase and Cajal body protein1) was isolated. This protein
is a component of active telomerase and interacts with
p23
TR
TEP1
GAR1
dyskerin
NOP10
TERT NHP2
Hsp 90
other 
subunits
Fig. 1 Human telomerase complex. hTR, human telomerase RNA;
hTERT, human Telomerase Reverse Transcriptase; Hsp90, heat shock
protein 90; P23, the Hsp90-associated protein; TEP1, telomerase-
associated protein 1; dyskerin, NHP2, NOP10, GAR1, members of
the H/ACA snoRNPs (small nucleolar ribonucleoproteins)
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with Cajal bodies (which deliver telomerase to chromo-
some ends) and with telomeres. Thus TCAB1 protein
facilitates to elongate telomeres by telomerase [99].
Telomeric proteins
Beyond multiple levels of telomerase activity regulation
presented in this review, an additional one exists. Interac-
tion of telomerase with numerous telomere binding pro-
teins (TBP) that may inﬂuence telomerase enzyme activity.
It is supposed that binding some of them to telomeres and
therefore making it impossible for telomerase to access the
chromosome ends is an indirect way of telomerase activity
regulation [51, 99].
A number of telomere binding proteins in human were
identiﬁed [100, 101] and shown to play crucial role in
telomere protection. They allow to distinguish telomeres
from damaged DNAs by forming telomere structure with D
and T loops and therefore prevent them from degradation
and fusion. Shelterin, a very dynamic structure, is impli-
cated in the generation of t-loops, and it controls the syn-
thesis of telomeric DNA by telomerase. All six shelterin
subunits (TRF1, TRF2, Rap1, TIN2, TPP1, POT1) can be
found in a single complex in fractionated nuclear extracts
[102, 103]. While shelterin complex seems to be respon-
sible for negative telomerase regulation, the POT1–TPP1
proteins may activate telomerase processivity in certain
conditions. Apparently, these two opposite functions of
POT1–TPP1 complex seem to be impossible. However, it
was proposed that POT1–TPP1 switches from inhibiting
telomerase access to the telomere, as a component of
shelterin, to serving as a processivity factor for telomerase
during telomere extension. Three-state model of telomere
length regulation was worked out [104]. At ﬁrst state POT1
is directly bound at the 30end of telomere and associates
with TPP1. This POT1–TPP1 position prevents binding of
telomerase to chromosome ends [100]. TPP1–POT1 asso-
ciation enhanced POT1 afﬁnity for telomeric ssDNA and
TPP1 associates with the telomerase, providing a physical
link between telomerase and the shelterin complex [105].
According to this model, these proteins are removed from
their binding sites by an unidentiﬁed mechanism. Post-
translational modiﬁcation or disruption of the shelterin
might be involved in that process. At third state, released
POT1–TPP1 complex may serve as an activator of telo-
merase during telomere extension. When elongated, telo-
mere reaches a certain threshold, the newly synthesized
repeats bind shelterin complexes and the 3’ end of the
overhang is re-bound by POT1–TPP1. This causes telo-
merase inhibition and return to the ﬁrst state of the complex
[105]. POT1 binds single stranded DNA at telomere end,
but the number of RNA r(UUAGGGUUNG) sequences
matching the POT1-binding site were identiﬁed [106].
Despite the possibility to bind with these RNAs, POT1
strongly binds only with telomeric DNA. Providing bind-
ing experiments with mixed DNA–RNA oligonucleotides
and a high resolution crystal structure it was shown that a
single ribouridine (rU4) instead of a deoxythymidine (dT4)
in a telomeric sequence d(GGTTAGGGTTAG) is the pri-
mary determinant of RNA discrimination by hPOT1 [107].
However, other authors suppose that some of the POT1–
TPP1 complexes are not associated with single stranded
DNA [108].
The TTAGGG repeat binding factor 1 and 2 (TRF1 and
TRF2, respectively) are the main proteins responsible for
negative feedback control in mammals. They are bound to
double stranded DNA at T-loop, which is a ‘‘closed’’ state
of telomere in which the telomerase enzyme cannot access
and therefore extends the telomere terminus. TRF1 and
TRF2 act as a negative regulators of telomeres length
because they are involved in T-loop formation [109, 110].
TRF1 and TRF2 were shown to act in cis to repress telo-
mere elongation. TRF1 was reported to repress the telo-
merase action on telomeres while, on the contrary, TRF2
appears to activate a telomeric degradation without show-
ing any inﬂuence on telomerase [111]. Another proteins
with the negative-feedback regulation of telomere length
have been identiﬁed in human cells. The proteins acting on
TRF1 are: Tankyrase 1 and 2 (TANK 1 and 2), TIN2,
PINX1, three TRF1-interacting factors but also hRAP1
which interacts with TRF2 [111, 112]. PINX1 can inhibit
telomerase by forming a stable complexes with catalytic
subunit of telomerase and TRF1 molecule. It binds with
TERT by its telomerase inhibitory domain (TID) placed at
C terminal 74 aa [80]. The human repressor activator
protein 1 (hRap1) was identiﬁed as a protein that speciﬁ-
cally interacts with TRF2 and negatively regulates telo-
mere length in vivo. It was shown that in addition to TRF2,
the hRap1 forms a complex with a multiple DNA repair
proteins: Rad50, Mre11, PARP1 (poly(ADP-ribose) poly-
merase), and Ku86/Ku70 [113]. One of these Ku proteins
has been proposed to be a direct regulator of human telo-
merase. It is a heterodimer of Ku70 and Ku 80 (or Ku 86)
subunits and it is involved in DNA repair pathway. It was
shown that Ku protein associated with human telomerase
both, in vivo and in vitro [114]. It was reported that Ku
associated with TERT and this interaction might regulate
the access of telomerase to telomeres. It is possible that the
association of telomerase with Ku might trap telomerase at
the double-stranded region of telomeric DNA and this
leads to decrease of the telomerase ability to access the
exposed 30 overhang [114]. On the contrary, other authors
showed that human Ku70/80 associated with TR both, in
vitro and in vivo. It was shown in TERT deﬁcient cell lines
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which suggested that Ku interacted directly with TR (with
a region of 47 nucleotides in the 30 end of TR precisely).
Thus, Ku may promote telomere elongation either by
recruiting TR to chromosome ends or by stabilizing
TR/TERT complexes once they form at the ends [115].
Therefore, it has been proposed that hRap1 associated with
TRF2 may indirectly regulate telomerase by recruitment or
regulation of Ku protein [113]. Recently, a novel protein
(MOV10 helicase) binding to G-strand of both single- and
double-stranded telomeric DNA was identiﬁed. MOV10
undergoes expression in human testis and ovary and seems
to be necessary to maintain telomerase activity in those
tissues. It is proven that MOV10 associates with TERT and
telomere and therefore probably takes part in the progres-
sion of telomere lengthening [116].
Summary and conclusions
Intensive studies of telomerase functioning in human cells
gave new perspectives on the mechanism of senescence,
stem cells and cancer therapy. The studies show that
numerous enzymes are required for telomerase functioning
that facilitate new approaches for inhibiting telomerase in
treating cancer. Probably there are still numerous unre-
vealed proteins that contribute to regulation of such a
dynamic complex. In conclusion, TERT expression is
regulated at both, the transcriptional and post-transcrip-
tional levels, and the alternative splicing of TERT is also
involved in the control of telomerase activity. However,
contradictive reports concern the correlation of telomere
length with telomerase activity or TERT expression in
different cells which might conﬁrm the tissue-speciﬁcity of
the regulatory mechanism. Since telomerase plays a very
important role in telomeres maintaining and thus it is
responsible for unlimited survival of cancer cell but also
for stem cells resources it seems very important to study
the enzyme in the context of anticancer therapy but also
tissue regeneration and aging.
One of the most promising strategies against telomerase
is RNA interference and antisense nucleotide which is
already in the second and even third clinic phase study
however, multiple side effects were observed which stop-
ped the enthusiasm about this method generally. Thus, the
study of telomerase activity regulation at the level of
enzymatic complex activity seems to give an alternative.
Anyway, it is still supposed to use both, activity and
expression regulation methods, as adjuvant therapies sim-
ilarly to G-quadruplex stabilization. Understanding of tel-
omerase activity may then bring a new insight into many
serious clinical problems that we have to face in aging
society.
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